3C Patch® is a first-in-class advanced biologic autologous cell therapy targeting hard-to-heal diabetic foot ulcers
(Birkerod, Denmark) – Reapplix, a privately-held, regenerative medicine company today announces, that coding details and reimbursement level have been set for its autologous platelet-rich plasma product 3C Patch® for the treatment of chronic non-healing diabetic wounds for up to 20 weeks. The completion of the transmittal follows the announcement of National Coverage Determination (NCD) in April 2021.
Under the established coding regime, the 3C Patch® application is reimbursed at a national average reimbursement rate of USD 1,715 per treatment, increasing to USD 1,759 from January 1st, 2022.
Following the issue of a change request by the Centers for Medicare and Medicaid Services (CMS), the Medicare Administrative Contractors (MACs) now have until November 9th, 2021 to update their systems enabling electronic handling of reimbursement claims from healthcare providers.
With clarification of coding and confirmation of reimbursement level, Reapplix now expects to expand sales efforts in the US by strengthening its sales organization in key metropolitan areas.
Kira Rupprecht, CEO of Reapplix says:
“We are very satisfied with the outcome of our efforts to bring our innovative 3C Patch® system to patients with diabetes and chronic wounds. Over the last five months, many wound care centres have been able to gain hands-on experience and training with the 3C Patch system on a trial basis. Given the positive results that their patients have experienced, these centres have been eagerly awaiting the reimbursement instructions that will now enable them to start treating a larger cross section of their patient base. With the removal of the last administrative and technical obstacles, caregivers can now seamlessly and with appropriate reimbursement conduct treatment with our innovative, autologous cell therapy helping patients to preserve their limbs and improve their healing.”
About 3C Patch®
3C Patch® draws on the body’s capacity to aid its own healing process and is an advanced biologic autologous cell therapy targeting hard-to-heal diabetic foot ulcers. The 3C Patch System is the first product of its kind utilising the patient’s own blood, without adding any reagents or additives, to produce a three-layered patch containing leukocyte cells, platelets and growth factors, enabling a more optimal healing environment, conducive in establishing a normal wound healing process. Its effectiveness is backed by solid clinical evidence, including a major international randomized controlled trial published in The Lancet Diabetes & Endocrinology in 2018.
Kira Rupprecht, Chief Executive Officer
+1 (949) 294-0806
Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. The patented 3CPatch® System is an innovative, evidence-based biological wound therapy made entirely from the patient’s own blood – nothing else. Headquartered in Denmark, with a dedicated sales and distribution team in the US, Reapplix is poised for commercial execution with particular focus on the US market.
Every wound is personal.